These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

190 related items for PubMed ID: 22678151

  • 1. The safety of peanut oral immunotherapy in peanut-allergic subjects in a single-center trial.
    Yu GP, Weldon B, Neale-May S, Nadeau KC.
    Int Arch Allergy Immunol; 2012; 159(2):179-82. PubMed ID: 22678151
    [Abstract] [Full Text] [Related]

  • 2. Allergen-specific oral immunotherapy for peanut allergy.
    Nurmatov U, Venderbosch I, Devereux G, Simons FE, Sheikh A.
    Cochrane Database Syst Rev; 2012 Sep 12; 2012(9):CD009014. PubMed ID: 22972130
    [Abstract] [Full Text] [Related]

  • 3. First Real-World Safety Analysis of Preschool Peanut Oral Immunotherapy.
    Soller L, Abrams EM, Carr S, Kapur S, Rex GA, Leo S, Lidman PG, Yeung J, Vander Leek TK, McHenry M, Wong T, Cook VE, Hildebrand KJ, Gerstner TV, Mak R, Lee NJ, Cameron SB, Chan ES.
    J Allergy Clin Immunol Pract; 2019 Sep 12; 7(8):2759-2767.e5. PubMed ID: 31002957
    [Abstract] [Full Text] [Related]

  • 4. A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy.
    Narisety SD, Frischmeyer-Guerrerio PA, Keet CA, Gorelik M, Schroeder J, Hamilton RG, Wood RA.
    J Allergy Clin Immunol; 2015 May 12; 135(5):1275-82.e1-6. PubMed ID: 25528358
    [Abstract] [Full Text] [Related]

  • 5. Probiotic peanut oral immunotherapy versus oral immunotherapy and placebo in children with peanut allergy in Australia (PPOIT-003): a multicentre, randomised, phase 2b trial.
    Loke P, Orsini F, Lozinsky AC, Gold M, O'Sullivan MD, Quinn P, Lloyd M, Ashley SE, Pitkin S, Axelrad C, Metcalfe JR, Su EL, Tey D, Robinson MN, Allen KJ, Prescott SL, Galvin AD, Tang MLK, PPOIT-003 study group.
    Lancet Child Adolesc Health; 2022 Mar 12; 6(3):171-184. PubMed ID: 35123664
    [Abstract] [Full Text] [Related]

  • 6. Feasibility of desensitizing children highly allergic to peanut by high-dose oral immunotherapy.
    Reier-Nilsen T, Michelsen MM, Lødrup Carlsen KC, Carlsen KH, Mowinckel P, Nygaard UC, Namork E, Borres MP, Håland G.
    Allergy; 2019 Feb 12; 74(2):337-348. PubMed ID: 30225844
    [Abstract] [Full Text] [Related]

  • 7. Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 study.
    Chinthrajah RS, Purington N, Andorf S, Long A, O'Laughlin KL, Lyu SC, Manohar M, Boyd SD, Tibshirani R, Maecker H, Plaut M, Mukai K, Tsai M, Desai M, Galli SJ, Nadeau KC.
    Lancet; 2019 Oct 19; 394(10207):1437-1449. PubMed ID: 31522849
    [Abstract] [Full Text] [Related]

  • 8. Safety of a peanut oral immunotherapy protocol in children with peanut allergy.
    Hofmann AM, Scurlock AM, Jones SM, Palmer KP, Lokhnygina Y, Steele PH, Kamilaris J, Burks AW.
    J Allergy Clin Immunol; 2009 Aug 19; 124(2):286-91, 291.e1-6. PubMed ID: 19477496
    [Abstract] [Full Text] [Related]

  • 9. Clinical efficacy and immune regulation with peanut oral immunotherapy.
    Jones SM, Pons L, Roberts JL, Scurlock AM, Perry TT, Kulis M, Shreffler WG, Steele P, Henry KA, Adair M, Francis JM, Durham S, Vickery BP, Zhong X, Burks AW.
    J Allergy Clin Immunol; 2009 Aug 19; 124(2):292-300, 300.e1-97. PubMed ID: 19577283
    [Abstract] [Full Text] [Related]

  • 10. Oral immunotherapy for peanut allergy: multipractice experience with epinephrine-treated reactions.
    Wasserman RL, Factor JM, Baker JW, Mansfield LE, Katz Y, Hague AR, Paul MM, Sugerman RW, Lee JO, Lester MR, Mendelson LM, Nacshon L, Levy MB, Goldberg MR, Elizur A.
    J Allergy Clin Immunol Pract; 2014 Aug 19; 2(1):91-6. PubMed ID: 24565775
    [Abstract] [Full Text] [Related]

  • 11. Peanut Allergen Threshold Study (PATS): Novel single-dose oral food challenge study to validate eliciting doses in children with peanut allergy.
    Hourihane JO, Allen KJ, Shreffler WG, Dunngalvin G, Nordlee JA, Zurzolo GA, Dunngalvin A, Gurrin LC, Baumert JL, Taylor SL.
    J Allergy Clin Immunol; 2017 May 19; 139(5):1583-1590. PubMed ID: 28238744
    [Abstract] [Full Text] [Related]

  • 12. Administration of a probiotic with peanut oral immunotherapy: A randomized trial.
    Tang ML, Ponsonby AL, Orsini F, Tey D, Robinson M, Su EL, Licciardi P, Burks W, Donath S.
    J Allergy Clin Immunol; 2015 Mar 19; 135(3):737-44.e8. PubMed ID: 25592987
    [Abstract] [Full Text] [Related]

  • 13. Peanut allergy and oral immunotherapy.
    Lee TH, Chan JKC, Lau PC, Luk WP, Fung LH.
    Hong Kong Med J; 2019 Jun 19; 25(3):228-234. PubMed ID: 31178442
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of high-dose peanut oral immunotherapy with factors predicting outcome.
    Anagnostou K, Clark A, King Y, Islam S, Deighton J, Ewan P.
    Clin Exp Allergy; 2011 Sep 19; 41(9):1273-81. PubMed ID: 21414048
    [Abstract] [Full Text] [Related]

  • 15. Peanut gastrointestinal delivery oral immunotherapy in adolescents: Results of the build-up phase of a randomized, double-blind, placebo-controlled trial (PITA study).
    Fauquert JL, Michaud E, Pereira B, Bernard L, Gourdon-Dubois N, Rouzaire PO, Rochette E, Merlin E, Evrard B, PITA Group.
    Clin Exp Allergy; 2018 Jul 19; 48(7):862-874. PubMed ID: 29665158
    [Abstract] [Full Text] [Related]

  • 16. Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy.
    Vickery BP, Scurlock AM, Kulis M, Steele PH, Kamilaris J, Berglund JP, Burk C, Hiegel A, Carlisle S, Christie L, Perry TT, Pesek RD, Sheikh S, Virkud Y, Smith PB, Shamji MH, Durham SR, Jones SM, Burks AW.
    J Allergy Clin Immunol; 2014 Feb 19; 133(2):468-75. PubMed ID: 24361082
    [Abstract] [Full Text] [Related]

  • 17. Low-dose oral immunotherapy for children with anaphylactic peanut allergy in Japan.
    Nagakura KI, Yanagida N, Sato S, Nishino M, Asaumi T, Ogura K, Ebisawa M.
    Pediatr Allergy Immunol; 2018 Aug 19; 29(5):512-518. PubMed ID: 29603410
    [Abstract] [Full Text] [Related]

  • 18. Early decrease in basophil sensitivity to Ara h 2 precedes sustained unresponsiveness after peanut oral immunotherapy.
    Patil SU, Steinbrecher J, Calatroni A, Smith N, Ma A, Ruiter B, Virkud Y, Schneider M, Shreffler WG.
    J Allergy Clin Immunol; 2019 Nov 19; 144(5):1310-1319.e4. PubMed ID: 31377342
    [Abstract] [Full Text] [Related]

  • 19. Oral immunotherapy using boiled peanuts for treating peanut allergy: An open-label, single-arm trial.
    Grzeskowiak LE, Tao B, Aliakbari K, Chegeni N, Morris S, Chataway T.
    Clin Exp Allergy; 2023 Mar 19; 53(3):327-336. PubMed ID: 36628520
    [Abstract] [Full Text] [Related]

  • 20. Modified peanut oral immunotherapy protocol safely and effectively induces desensitization.
    Bird JA, Feldman M, Arneson A, Dougherty I, Brown LS, Burk CM, Kulis M, Burks W, Gill M.
    J Allergy Clin Immunol Pract; 2015 Mar 19; 3(3):433-5.e1-3. PubMed ID: 25609341
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.